Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: amadeus who wrote (14590)	9/6/2001 5:28:33 PM
From: quasi-geezer	Read Replies (1) \| Respond to of 208838

you mean this article MacroChem tumbles after impotence gel disappoints NEW YORK, Sept 6 (Reuters) - Shares of MacroChem Corp. (NasdaqNM:MCHM - news) lost a third of their value on Thursday after the Massachusetts biotech firm cited disappointing trial results for its topical anti-impotence drug, Topiglan. ADVERTISEMENT MacroChem was down $2.00 to $4.15, or 33 percent, the second-biggest percentage loser in morning trade on the Nasdaq. The Lexington, Massachusetts-based company said late on Wednesday the gel improved erectile function in a subset of patients, despite drug potency problems, but that data failed to show it helped erections last through ejaculation. MacroChem said the study showed ``positive direction but not statistical significance in the ability to maintain erection to completion of intercourse, a benchmark typically required for approval of an ED (erectile dysfunction) drug.'' Men apply Topiglan to the glans (head) of the penis. Unlike Pfizer Inc's (NYSE:PFE - news) famous anti-impotence pill, Viagra, MacroChem has said Topiglan (alprostadil) can be used by men taking organic nitrate heart drugs. MacroChem said a sampling of unused patient doses showed potency of Topiglan was below design specifications in a significant percentage of samples tested. It said the problem likely resulted from interaction with components of the dispenser used in the trial and that the company has since developed a blister-type dispenser it expects to use in subsequent studies. I think I applied the stupid thing correctly, how come it does not work ...